Shots:
- Sciwind Biosciences has granted Pfizer China exclusive commercialization rights to Ecnoglutide injection in Mainland China
- As per the deal, Sciwind will retain the MA & will be responsible for R&D, registration, manufacturing, & supply, plus is eligible to receive ~$495M in upfront, regulatory, & sales milestones
- Independently developed by Sciwind, Ecnoglutide is a cAMP-biased GLP-1 receptor agonist approved by China’s NMPA in Jan 2026 for adult type 2 diabetes, with its MAA for adult chronic weight management currently under NMPA review
Ref: PRnewswire |  Image: Sciwind & Pfizer |  Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
